semaglutide alzheimer's trial Blockbuster GLP-1 Diabetes and Weight Loss Drugs Fails in Efficacy and safety of oral

Ozempic (semaglutide) is a weekly prescription medication that is approved by the Food and Drug Administration (FDA) to help control blood glucose levels in people with Type 2 diabetes

Its also important to understand that individual responses vary

If it doesnt dissolve immediately, continue to gently swirl the vial or let it sit at room temperature for a few minutes

Study Strengths & Limitations Strengths: Large, international, double-blind RCT with adjudicated endpoints Comprehensive, repeated adiposity measures using standardised protocols Sophisticated statistical handling including multiple imputation models for missing data Pre-specified analysis with clear hypotheses Limitations: Predominantly White (77%) and male (63%) cohortgeneralisability to other populations requires confirmation Industry-funded (Novo Nordisk), though with independent academic oversight Post-randomisation analyses of weight/waist changes are observational and cannot prove causation The paradoxical association in placebo between weight loss and increased MACE suggests unintentional weight loss from comorbiditya key confounder The Bottom Line for Clinicians Semaglutide provides robust cardiovascular protection in patients with obesity and established CVD, independent of baseline adiposity and largely independent of weight-loss magnitude

Enrolling 17,604 adults aged 45 or older with established cardiovascular disease and a BMI of 27 or higher (without diabetes), SELECT showed that semaglutide 2.4 mg reduced the composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke by 20% over a mean follow-up of nearly 40 months